Quarterly ResultMay 12, 2026, 04:12 PM
Bolt Biotherapeutics Q1 Net Loss $7.2M; BDC-4182 Data in 3Q 2026
AI Summary
Bolt Biotherapeutics reported a net loss of $7.2 million for the first quarter ended March 31, 2026, an improvement from $11.0 million in the prior year, primarily due to reduced R&D and G&A expenses. The company's cash balance of $23.9 million is anticipated to fund operations into 2027. Bolt's lead immune-stimulating antibody conjugate, BDC-4182, is progressing in its Phase 1/2 study, with initial clinical data expected in the third quarter of 2026.
Key Highlights
- Net loss for Q1 2026 was $7.2 million, an improvement from $11.0 million in Q1 2025.
- Collaboration revenue decreased to $26,000 in Q1 2026 from $1.2 million in Q1 2025.
- R&D expenses fell to $4.8 million in Q1 2026 from $9.5 million in Q1 2025.
- G&A expenses decreased to $2.8 million in Q1 2026 from $3.8 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $23.9 million as of March 31, 2026.
- Cash balance is expected to fund operations into 2027.
- Initial clinical data for BDC-4182 Phase 1/2 study expected in Q3 2026.